An open-label multi-center everolimus roll-over protocol for patients who have completed a previous Novartis-sponsored everolimus study and are judged by the investigator to benefit from continued everolimus treatment
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
To allow continued use of everolimus to patients receiving everolimus in a Novartis-sponsored Oncology CD&MA study which has reached its objectives and who are benefitting from treatment with everolimus.
Description
To allow continued use of everolimus to patients receiving everolimus in a Novartis-sponsored Oncology CD&MA study which has reached its objectives and who are benefitting from treatment with everolimus.
Details
| Condition | Kidney Cancer |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX3350 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.